Breakthrough in Anti-Aging: David Sinclair's Team Reveals Exciting Results of Super NMN
David Sinclair's team, renowned for anti-aging breakthroughs, introduces MIB-626, a robust NMN derivative. Published in "The Journal of Clinical Endocrinology & Metabolism," a 28-day trial on 30 participants demonstrates MIB-626's safety and efficacy. Results reveal a 200% increase in NAD+ levels, influencing metabolism positively. Participants experienced weight loss, improved cholesterol levels, and reduced blood pressure. Despite study challenges—participant count and trial duration—Metro Biotech pursues three ongoing trials. While improvements are essential, the study emphasizes MIB-626's potential and anticipates future trials to provide clearer insights. The goal remains an early launch of an accessible anti-aging drug.
Lebih banyak+